{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 457123707
| type = mab
| image = 
| alt = 
| mab_type = mab
| source = xi/o
| target = MUC5AC
| tradename = 
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = 
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 1092658-06-4
| ATC_prefix = none
| ATC_suffix = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = F988K568V2
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D09898
| C=6342 | H=9800 | N=1678 | O=1985 | S=46
| molecular_weight = 142.8 kg/mol
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
}}

'''Ensituximab''' ('''NPC-1C''') is a chimeric monoclonal antibody under [[drug development|development]] for as a candidate for treatment of cancers.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf}}</ref> The [[drug target|target]] of the antibody is uncertain and is described as "human colorectal and pancreatic carcinoma-associated antigens", a set of [[tumor antigen]]s isolated from human cancers.<ref>{{cite web|title=Ensituximab|url=https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=663436|publisher=NCI Drug Dictionary|accessdate=31 January 2017|language=en}}</ref>  The target might be [[Mucin 5AC]].<ref name=JoP2012>{{cite journal|last1=Strimpakos|first1=Alexios S.|last2=Syrigos|first2=Kostas N.|last3=Saif|first3=Muhammad Wasif|title=Novel Agents in Early Phase Clinical Studies on Refractory Pancreatic Cancer|journal=JOP. Journal of the Pancreas|date=10 March 2012|volume=13|issue=2|pages=166–168|pmid=22406592|url=http://www.serena.unina.it/index.php/jop/article/view/714/822|language=en|issn=1590-8577}}</ref>

The antibody was discovered by scientists at Neogenix Oncology using [[tumor antigen]]s that had been identified years earlier by [[Ariel Hollinshead]]; the founder of Neogenix had founded a prior company based on Hollinshead's work as well.<ref>{{cite news|last1=Morrison|first1=Trista|title=Neogenix Uses Cancer Vaccine And Antibody Approaches|work=BioWorld Today|date=July 11, 2007|url=http://www.bioworld.com/content/newco-news-neogenix-uses-cancer-vaccine-and-antibody-approaches}}</ref>  Neogenix worked with Selexis to develop the [[CHO cell]] line expressing ensituximab<ref>Neogenix Oncology, Inc. - Pharmaceuticals & healthcare - Deals and alliances profile. (2015). London: Global Data Ltd.</ref><ref>{{cite web|title=Press ReleaseL Selexis and Neogenix Oncology Execute Commercial License Agreement - Selexis SA|url=http://www.selexis.com/selexis-neogenix-oncology-execute-commercial-license-agreement/|publisher=Selexis SA|date=5 January 2011}}</ref> and also worked with Goodwin Biotechnology Inc on process development.<ref>{{cite web|title=From Vaccines To Monoclonal Antibodies: Creating Milestones In Cancer Theranostics|url=http://www.growthconsulting.frost.com/web/images.nsf/0/DFB3A440F8FFB11C65257363001AC49E/$File/TI%20Alert.htm|publisher=Frost & Sullivan|date=14 September 2007}}</ref>

Ensituximab was granted [[orphan drug designation]] for pancreatic cancer by the FDA in 2010.<ref>{{cite news|last1=Staff|title=FDA Pipeline Preview, December 2010 (Ezogabine, Solesta, Dutasteride, Finasteride, Octaplex, SF1126, MP4CO, Ensituximab, Naloxone, CBLB502)|url=http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/fda-pipeline-preview-december-2010-ezogabine-s|work=Formulary Journal|date=1 December 2010|language=en}}</ref>  Results from a small Phase II trial in people with pancreatic or colon cancer presented in 2012 were not promising with regard to efficacy in treating pancreatic cancer.<ref name=JoP2012/>

In 2011 Neogenix was forced to declare bankruptcy because the SEC opened an investigation into its use of unregistered [[broker-dealers]] in the course of raising $30M, and it could not raise further funds; in 2012 Neogenix sold its assets to a group of its investors who had formed a company called Precision Biologics.<ref>{{cite news|last1=Davie|first1=Alexander J.|title=Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 1: How It All Happened|url=https://www.strictlybusinesslawblog.com/2012/10/05/neogenix-oncology-a-good-case-study-on-securities-law-noncompliance-by-a-high-growth-company-part-1-how-it-all-happened/|work=Strictly Business|date=5 October 2012}}.  {{cite news|title=Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 2: What Neogenix Did|url=https://www.strictlybusinesslawblog.com/2012/10/24/neogenix-oncology-a-good-case-study-on-securities-law-noncompliance-by-a-high-growth-company-part-2-what-neogenix-did/|work=Strictly Business|date=24 October 2012}}.  {{cite news|title=Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 3: When the Genie Can’t Be Put Back in the Bottle|url=https://www.strictlybusinesslawblog.com/2012/11/16/neogenix-oncology-a-good-case-study-on-securities-law-noncompliance-by-a-high-growth-company-part-3-when-the-genie-cant-be-put-back-in-the-bottle/|work=Strictly Business|date=17 November 2012}}</ref>

In 2016, Precision released data from a Phase II trial colorectal cancer and at that time was working with Cytovance Biologics as its [[contract manufacturing organization]].<ref>{{cite web|title=Ensituximab|url=http://adisinsight.springer.com/drugs/800031614|publisher=AdisInsight|accessdate=30 January 2017|language=en}}</ref>

== References ==

<references/>

{{monoclonals for tumors}}

[[Category:Monoclonal antibodies]]
[[Category:Experimental cancer drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}